KITPROZY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KITPROZY (KITPROZY).
Stimulates endogenous erythropoietin production by inhibiting the von Hippel-Lindau (VHL) protein, thereby stabilizing hypoxia-inducible factor (HIF)-2α and activating erythropoietin gene transcription.
| Metabolism | Primarily metabolized by CYP2C8 and CYP3A4; also undergoes glucuronidation via UGT1A9. |
| Excretion | Primarily renal excretion of unchanged drug (70-80%) with biliary/fecal elimination accounting for 15-20%. Less than 5% excreted as metabolites. |
| Half-life | Terminal elimination half-life is approximately 12-15 hours in healthy adults, extending to 24-30 hours in moderate renal impairment (CrCl 30-59 mL/min). |
| Protein binding | Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive tissue distribution and moderate penetration into peripheral compartments. |
| Bioavailability | Oral bioavailability is 60-70% due to first-pass metabolism; IM bioavailability is 85-90%. |
| Onset of Action | Intravenous: 5-10 minutes; Oral: 30-60 minutes. |
| Duration of Action | 12-24 hours depending on dose and route, with IV providing shorter duration due to peak effects. Clinical effect persists for 6-8 hours at standard doses. |
1400 mg intravenously over 60 minutes every 3 weeks until disease progression or unacceptable toxicity.
| Dosage form | VIAL |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min) or end-stage renal disease. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients under 18 years of age. |
| Geriatric use | No specific dose adjustment recommended. Clinical studies included patients ≥65 years; adverse event profile similar to younger adults, but monitor renal function and comorbidities closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for KITPROZY (KITPROZY).
| Breastfeeding | No data on presence in human milk; animal studies suggest excretion. M/P ratio unknown. Potential for serious adverse reactions in breastfed infants (e.g., immunosuppression). Breastfeeding is not recommended during treatment and for 3 months after last dose. |
| Teratogenic Risk | KITPROZY is contraindicated in pregnancy. First trimester: Increased risk of major congenital malformations including cardiac and neural tube defects based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm delivery. Pregnancy must be excluded before initiation, and effective contraception required during treatment and for 3 months after last dose. |
■ FDA Black Box Warning
Increased risk of mortality, myocardial infarction, stroke, venous thromboembolism, and tumor progression or recurrence. Use the lowest dose necessary to avoid red blood cell transfusion.
| Serious Effects |
Uncontrolled hypertension; history of serious hypersensitivity reaction to vadadustat or any component of the formulation; severe hepatic impairment.
| Precautions | Increased risk of thromboembolic events; monitor hemoglobin levels and adjust dose to avoid excessive erythropoiesis; hypertension; potential for tumor progression in cancer patients; serious hypersensitivity reactions; gastrointestinal ulceration and bleeding. |
Loading safety data…
| Fetal Monitoring | Prior to pregnancy: Negative pregnancy test should be confirmed. During treatment: Frequent pregnancy tests if any potential for pregnancy. Monitor for fetal growth via ultrasound if pregnancy occurs. No specific maternal monitoring required beyond standard care. |
| Fertility Effects | Based on animal studies, KITPROZY may impair fertility in females (reduced ovarian follicular development) and males (decreased sperm count and motility). Reversible upon discontinuation. Human data lacking; counsel patients on fertility preservation options. |